Radiation therapy for ventricular arrhythmias.
Xingzhou Liulu1, Poornima Balaji2,3, Jeffrey Barber4,5
1Cardiology Department, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Summary
Stereotactic body radiotherapy offers a non-invasive approach to treat life-threatening ventricular arrhythmias (VA) when catheter ablation fails. This novel modality overcomes limitations of traditional treatments by delivering energy to previously unreachable areas, showing promise in clinical trials.
Area of Science:
- Cardiology
- Radiation Oncology
- Medical Physics
Background:
- Ventricular arrhythmias (VA) are serious heart rhythm disorders linked to high morbidity and mortality.
- Catheter ablation (CA) is an invasive option for refractory VA, but recurrence is common due to limitations in lesion depth and reach.
- Existing treatments struggle to address deep or scarred cardiac tissue driving VA.
Purpose of the Study:
- To review the current evidence for stereotactic body radiotherapy (SBRT) as a treatment for ventricular arrhythmias.
- To evaluate SBRT's potential to overcome the limitations of catheter ablation in treating refractory VA.
- To outline the necessary steps for integrating SBRT into mainstream VA treatment.
Main Methods:
- Review of existing clinical trials and literature on SBRT for VA.
- Analysis of SBRT's mechanism of action in ablating cardiac electrical circuits.
- Comparison of SBRT's efficacy and safety profile against conventional treatments.
Main Results:
- SBRT has shown success in small clinical trials for treating refractory VA.
- The non-invasive nature of SBRT allows volumetric energy delivery to target inaccessible arrhythmogenic areas.
- SBRT addresses the limitations of CA, particularly in cases of deep-seated or scar-related arrhythmias.
Conclusions:
- Stereotactic body radiotherapy is a promising novel treatment for ventricular arrhythmias.
- SBRT offers a non-invasive alternative that overcomes key limitations of catheter ablation.
- Further steps are needed to establish SBRT as a frontline therapy for refractory VA.
Related Concept Videos
01:28Disturbances in Heart Rhythm
945
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
945
01:28Mechanism of Cardiac Arrhythmias
917
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
917
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
980
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
980
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K